跳至主要内容
临床试验/NCT00322283
NCT00322283已完成2 期

Efficacy and Safety of Oglemilast in the Prevention of Exercise-Induced Bronchospasm

Forest Laboratories1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2006年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
To determine the efficacy of oglemilast as compared to placebo in preventing exercise-induced asthma following 15 days of treatment.

研究概览

简要总结

The purpose of this study is to determine whether it is effective in the treatment of exercise-induced asthma and investigate the safety of oglemilast.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • stable mild asthma patients who exhibit at least a 20% decrease in FEV1 following exercise.

排除标准

  • pulmonary disease other than asthma, psychiatric illness, active cardiac disease, high blood pressure, history of substance abuse, current smokers.

研究组 & 干预措施

Oglemilast

Experimental

干预措施: Oglemilast (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

To determine the efficacy of oglemilast as compared to placebo in preventing exercise-induced asthma following 15 days of treatment.

次要结局

  • To evaluate the safety of oglemilast over 2 weeks as determined by adverse events, physical examinations, vital signs, electrocardiograms, and laboratory examinations.

研究者

发起方
Forest Laboratories
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Study of Oglemilast for the Prevention of Asthma. | 临床试验